Document is current

Article History

Received: 5 September 2023

Accepted: 21 March 2024

First Online: 25 April 2024

Declarations

:

: The ethical principles for medical research as stated by the Declaration of Helsinki, were applied throughout the study []. The study is reported in line with CONSORT 2010 statements for pilot and feasibility trials []. The study was approved by the Regional Committees on Health Research Ethics for Southern Denmark (S-20210046). Methods have followed guidelines and regulation given by the Regional Committees on Health Research Ethics for Southern Denmark. Consent forms and process have been ethically reviewed by the Regional Committees on Health Research Ethics for Southern Denmark. All participants provided written informed consent. Written informed consent was obtained from all participants by the principal investigator.The pilot-study was registered at the Research & Innovation Organisation (RIO), University of Southern Denmark, record of data processing activities, (Project identification number: 11.404). Data was processed and stored in accordance with EU General Data Protection Regulation (GDPR) and the Danish Data Protection Act.

: Not applicable.

: SAS declare no competing interest.CBL has in the past 36 months received speaker’s honoraria for lectures at educational events / symposia / courses organised by AstraZeneca, royalties as author of book chapters or as editor of books / web publications by Munksgaard.DEJ declare no competing interest.FSR declare no competing interest.KAR declare no competing interest.